Scholarlink

Purpose of Review <p>This review aims to synthesize current evidence on metabolic dysfunction-associated steatotic liver disease (MASLD) as a systemic driver of extrahepatic complications beyond its hepatic manifestations. We sought to answer two key questions: (1) Which multisystemic diseases show independent associations with MASLD after adjustment for traditional cardiometabolic risk factors? (2) What shared pathophysiological mechanisms link hepatic steatosis to distant organ dysfunction?</p> Recent Findings <p>Large cohort studies and meta-analyses demonstrate MASLD independently increases cardiovascular, renal, gastrointestinal, and oncologic risks, independently from traditional cardiometabolic risk factors. Key mechanisms include systemic inflammation, insulin resistance with hyperinsulinemia, endothelial dysfunction, visceral adipose tissue dysregulation, gut dysbiosis with metabolic endotoxemia, atherogenic dyslipidemia, PNPLA3 genetic variants, and oxidative stress. Hepatic fibrosis consistently amplifies multisystemic risk across organ systems.</p> Summary <p>MASLD represents a multisystem metabolic disorder requiring integrated risk assessment. Systematic fibrosis staging emerges as the strongest disease-specific prognostic factor. Future research must develop risk prediction models and liver-directed interventions targeting the gut-liver axis to mitigate MASLD's growing population-level burden</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MASLD Beyond the Liver: A Systemic Driver of Cardiovascular, Renal, and Oncologic Risk

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Antonio Liguori,
  • Valentin Calvez,
  • Lucrezia Petrucci,
  • Fabrizio Termite,
  • Lidia Tomasello,
  • Angela Sciarra,
  • Simone Varca,
  • Antonio Gasbarrini,
  • Maurizio Pompili,
  • Luca Miele

摘要

Purpose of Review

This review aims to synthesize current evidence on metabolic dysfunction-associated steatotic liver disease (MASLD) as a systemic driver of extrahepatic complications beyond its hepatic manifestations. We sought to answer two key questions: (1) Which multisystemic diseases show independent associations with MASLD after adjustment for traditional cardiometabolic risk factors? (2) What shared pathophysiological mechanisms link hepatic steatosis to distant organ dysfunction?

Recent Findings

Large cohort studies and meta-analyses demonstrate MASLD independently increases cardiovascular, renal, gastrointestinal, and oncologic risks, independently from traditional cardiometabolic risk factors. Key mechanisms include systemic inflammation, insulin resistance with hyperinsulinemia, endothelial dysfunction, visceral adipose tissue dysregulation, gut dysbiosis with metabolic endotoxemia, atherogenic dyslipidemia, PNPLA3 genetic variants, and oxidative stress. Hepatic fibrosis consistently amplifies multisystemic risk across organ systems.

Summary

MASLD represents a multisystem metabolic disorder requiring integrated risk assessment. Systematic fibrosis staging emerges as the strongest disease-specific prognostic factor. Future research must develop risk prediction models and liver-directed interventions targeting the gut-liver axis to mitigate MASLD's growing population-level burden